What they were paid
Longboard Pharmaceuticals Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | — | $0 | — | $0 | — |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Longboard Pharmaceuticals, Inc. DEF 14A filed April 12, 2024, accession 0000950170-24-044023, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2023Longboard Pharmaceuticals pays directors a $40,000 cash retainer and $58,815 in equity.
Committees
FY2023 · as the proxy prints themCompensation · Nominating/Governance
The rest of the Longboard Pharmaceuticals board
FY2023 · as the company reported each| Director | Role | FY2023 total |
|---|---|---|
| Casey C. Lynch | Independent Director | $112,799 |
| Corinne Le Goff | Independent Director | — |
| Kevin R. Lind | Director | $0 |
| Paul J. Sekhri | Chair of the Board | $145,807 |
| Phillip M. Schneider | Independent Director | $121,803 |
| Vincent E. Aurentz | Independent Director | $109,344 |
The full Longboard Pharmaceuticals compensation record
free company briefThis page is one director within Longboard Pharmaceuticals's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat